CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 55 filers reported holding CORVUS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $458,000 | -78.5% | 200,000 | -91.5% | 0.14% | -75.4% |
Q1 2023 | $2,128,856 | +5.0% | 2,339,402 | -1.9% | 0.56% | +4.6% |
Q4 2022 | $2,026,742 | +3.8% | 2,384,402 | 0.0% | 0.54% | +2.9% |
Q3 2022 | $1,952,000 | -10.9% | 2,384,402 | +7.7% | 0.52% | -37.3% |
Q2 2022 | $2,192,000 | -21.5% | 2,214,184 | +30.0% | 0.84% | -29.5% |
Q1 2022 | $2,793,000 | +189.7% | 1,703,137 | +325.8% | 1.19% | +271.2% |
Q4 2021 | $964,000 | +20.0% | 400,000 | +141.1% | 0.32% | +36.8% |
Q3 2021 | $803,000 | -58.2% | 165,927 | -76.9% | 0.23% | -47.7% |
Q2 2021 | $1,920,000 | -8.2% | 719,132 | +5.9% | 0.45% | +6.7% |
Q1 2021 | $2,092,000 | +19.7% | 679,132 | +38.4% | 0.42% | -14.8% |
Q4 2020 | $1,748,000 | -25.3% | 490,877 | -15.8% | 0.49% | -40.9% |
Q3 2020 | $2,339,000 | +136.3% | 583,232 | +60.2% | 0.83% | +115.5% |
Q2 2020 | $990,000 | +28.9% | 364,132 | 0.0% | 0.39% | -78.7% |
Q1 2020 | $768,000 | -61.9% | 364,132 | -1.7% | 1.81% | +19.2% |
Q4 2019 | $2,014,000 | +71.4% | 370,307 | -5.1% | 1.52% | +32.8% |
Q3 2019 | $1,175,000 | – | 390,307 | – | 1.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 3,749,379 | $18,147,000 | 3.77% |
VR Adviser, LLC | 3,427,461 | $16,589,000 | 2.13% |
ADAMS STREET PARTNERS LLC | 3,275,616 | $15,854,000 | 2.04% |
Telemetry Investments, L.L.C. | 196,168 | $949,000 | 1.28% |
DC Investments Management, LLC | 50,709 | $245,000 | 0.46% |
Orbimed Advisors | 6,943,654 | $33,607,000 | 0.37% |
EcoR1 Capital, LLC | 2,081,077 | $10,072,000 | 0.35% |
BVF INC/IL | 1,370,947 | $6,635,000 | 0.26% |
Ikarian Capital, LLC | 757,545 | $3,666,000 | 0.26% |
CHI Advisors LLC | 165,927 | $803,000 | 0.23% |